Retisert Bausch & Lomb/control delivery systems

Current Opinion in Investigational Drugs

Volumn 6, Issue 11, 2005, Pages 1159-1167

  Lim, Lyndell L ^a   Smith, Justine R ^a   Rosenbaum, James T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; ENVISION; FLUOCINOLONE ACETONIDE; GANCICLOVIR; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSURDEX; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CATARACT; CATARACT EXTRACTION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG IMPLANT; DRUG METABOLISM; DRUG PELLET; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EYE INFECTION; FILTERING OPERATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; NONHUMAN; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINITIS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SUSTAINED RELEASE PREPARATION; SYSTEMIC DISEASE; THERAPY RESISTANCE; UVEITIS; VISUAL IMPAIRMENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; DRUG IMPLANTS; FLUOCINOLONE ACETONIDE; HUMANS; MACULAR EDEMA, CYSTOID; PATENTS; RANDOMIZED CONTROLLED TRIALS; STRUCTURE-ACTIVITY RELATIONSHIP; UVEITIS, POSTERIOR;

EID: 28244456234     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. 365086 Bausch & Lomb moves another step closer to providing breakthrough treatment to millions with sight-threatening eye diseases. Bausch & Lomb Inc PRESS RELEASE 2000 May 03
2. 395221 Pivotal studies using Envision TD technology for diabetic macular edema and posterior uveitis are underway - Bausch & Lomb announces enrollment at first patients in pivotal clinical studies. Bausch & Lomb Inc PRESS RELEASE 2001 January 05
3. 493690 Analysis of 12-month data from diabetic macular edema clinical trial sponsored by Bausch & Lomb and Control Delivery Systems to be presented at ARVO 2003. When second trial data is analyzed, sponsors will assess the impact on the DME development program of a delay of up to three years in U.S. NDA filing. Control Delivery Systems Inc PRESS RELEASE 2003 May 07
4. 493701 Bausch & Lomb and Control Delivery Systems announce results of first phase III clinical trial of envision TD ophthalmic implant for treatment of diabetic macular edema. Control Delivery Systems Inc PRESS RELEASE 2002 June 06
5. 493702 Control Delivery Systems announces increased funding for collaboration with Bausch & Lomb on sight-threatening eye diseases. Control Delivery Systems Inc PRESS RELEASE 2002 May 07
6. 495015 BIO 2003 - International Biotechnology Convention and Exhibition (Part VII), Washington, DC, USA. Aird J IDDB MEETING REPORT 2003 June 21-25
7. 496321 Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P INVEST OPHTHALMOL VIS SCI 2000 41 11 3569-3575
8. 505887 Results of 34-week data from posterior uveitis clinical trial sponsored by Bausch & Lomb presented at Retina Society. PRESS RELEASE 2003 September 22
9. 513391 Data analysis from clinical trials of Bausch & Lomb's Retisert implant for posterior uveitis and diabetic macular edema presented at American Academy of Ophthalmology. Bausch & Lomb Inc PRESS RELE4SE 2003 November 14
10. 562350 34-Week data analysis from second clinical trial of Bausch & Lomb's Retisert implant for posterior uveitis is presented at the Retina Society Annual Meeting. Bausch & Lomb Inc PRESS RELEASE 2004 October 04
11. 594411 FDA approves Bausch & Lomb's patented Retisert orphan drug. Bausch & Lomb Inc PRESS RELEASE 2005 April 11
12. 599230 Two-Year date from clinical trial of Retisert presented at ARVO. Bausch & Lomb Inc PRESS RELEASE 2005 May 03
13. 612208 Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. Driot J-Y, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA J OCUL PHARMACOL THER 2004 20 3 269-275
14. 612219 Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P OPHTHALMOLOGY 2005 112 7 1192-1198
15. 612222 Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Jaffe GJ, Ben-nun J, Guo H, Dunn JP, Ashton P OPHTHALMOLOGY 2000 107 11 2024-2033
16. 612978 An intravitreal sustained-release fluocinolone acetonide device to treat severe experimental uveitis. Mruthyunjaya P, Khalatbari D, Yang P, Stinnet S, Hanes M, Jaffe GJ ANN MEET ASSOC RES VISION OPHTHALMOL 2003 Abs 4215
17. 619265 Management of immune-mediated uveitis. Smith JR, Rosenbaum JT BIODRUGS 2000 13 1 9-20
18. 619274 Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D AM J OPHTHALMOL 2000 130 4 492-513
19. 619279 The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. AM J OPHTHALMOL 2001 131 4 457-467.
20. 619281 Sustained release intravitreal dexamethasone. Hainsworth DP, Pearson PA, Conklin JD, Ashton P J OCUL PHARMACOL THER 1996 12 1 57-63
21. 619283 An intravitreal device providing sustained release of cyclosporine and dexamethasone. Enyedi LB, Pearson PA, Ashton P, Jaffe GJ CURR EYE RES 1996 15 5 549-557
22. 619286 Evaluation of a delivery system providing long-term release of cyclosporine. Pearson PA, Jaffe GJ, Martin DF, Cordahi GJ, Grossniklaus H, Schmeisser ET, Ashton P ARCH OPHTHALMOL 1996 114 3 311-317
23. 619287 Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Cheng CK, Berger AS, Pearson PA, Ashton P, Jaffe GJ INVEST OPHTHALMOL VIS SCI 1995 36 2 442-453
24. 619288 Intravitreal-sustained release fluocinolone acetonide device to treat severe experimental uveitis. Srivastava S, Mruthyunjaya P, Wiser J, Peairs J, Stinnet S, Jaffe G INVEST OPHTHALMOL VIS SCI 2005 46 Abs 3536
25. 619291 Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R BR J OPHTHALMOL 2003 87 4 462-468
26. 619293 The safety profile of long-term, high-dose intraocular corticosteroid delivery. Holekamp NM, Thomas MA, Pearson A AM J OPHTHALMOL 2005 139 3 421-428
27. 619298 Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Jonas JB, Kreissig I, Sofker A, Degenring RF ARCH OPHTHALMOL 2003 121 1 57-61
28. 619300 Intravitreal triamcinolone for refractory diabetic macular edema. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C OPHTHALMOLOGY 2002 109 5 920-927
29. 619302 Bioerodable eye implant may help treat macular edema - in the field. Russell R PHARM TECHNOL 2004 March
30. 619566 Management of uveitis: A rheumatologic perspective. Smith JR, Rosenbaum JT ARTHRITIS RHEUM 2002 46 2 309-318
31. 619570 Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Jaffe GJ, Pearson PA, Ashton P RETINA 2000 20 3 402-403
32. 619573 Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Danis RP, Ciulla TA, Pratt LM, Anliker W RETINA 2000 20 3 244-250
33. 619793 Fluocinolone acetonide intravitreal implant for uveitis affecting the posterior segment of the eye. Jaffe G ANN MEET ASSOC RES VISION OPHTHALMOL 2004 Abs 3369
34. 619794 Fluocinolone acetonide intravitreal implant for diabetic macular edema: 2 year results. Pearson P, Baker C, Eliot D, Morse L, Callanan D ANN MEET ASSOC RES VISION OPHTHALMOL 2004 Abs 1111
35. 623020 Immune system disorders. McComb CC, DeShato RD AVERYS DRUG TREATMENT, FOURTH EDITION. Eds: Speight TM, Holford NHG 1997 1295-1345
36. 623023 Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg formulary kit. Bausch & Lomb Inc COMPANY BROCHURE 2005 May
37. 625813 Fluocinolone acetonide intravitreal implant to treat posterior uveitis: 2-year results of a multi-center clinical trial. Jaffe GJ, Martin D, Callanan D, Levy B ANN MEET ASSOC RES VISION OPHTHALMOL 2005 Abs 2386
38. 626456 pSivida to acquire Control Delivery Systems. pSivida Ltd PRESS RELEASE 2005 October 03
39. 626793 Bausch & Lomb Incorporated (BOL) reports positive Q2-05, maintain outperform rating. Wong SS, Johnson JD, Tepe RB ROBERT W BAIRD CO INC 2005 1-12
40. 630478 Bausch & Lomb fourth-quarter sales up 15 percent, comparable-basis EPS rise 38 percent. Bausch & Lomb Inc PRESS RELEASE 2004 January 29